ATE240746T1 - Immunovektoren zum transport in die zelle und den zellkern - Google Patents

Immunovektoren zum transport in die zelle und den zellkern

Info

Publication number
ATE240746T1
ATE240746T1 AT96924965T AT96924965T ATE240746T1 AT E240746 T1 ATE240746 T1 AT E240746T1 AT 96924965 T AT96924965 T AT 96924965T AT 96924965 T AT96924965 T AT 96924965T AT E240746 T1 ATE240746 T1 AT E240746T1
Authority
AT
Austria
Prior art keywords
cell
biologically active
immunovectors
transport
active principle
Prior art date
Application number
AT96924965T
Other languages
English (en)
Inventor
Stratis Avrameas
Gerard Buttin
Therese Ternynck
Faridabano Nato
Original Assignee
Pasteur Institut
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Univ Paris Curie filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE240746T1 publication Critical patent/ATE240746T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AT96924965T 1995-07-10 1996-07-10 Immunovektoren zum transport in die zelle und den zellkern ATE240746T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9508316A FR2736642B1 (fr) 1995-07-10 1995-07-10 Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
PCT/FR1996/001076 WO1997002840A1 (fr) 1995-07-10 1996-07-10 Immunovecteurs utilisables pour le transport intracellulaire et intranucleaire

Publications (1)

Publication Number Publication Date
ATE240746T1 true ATE240746T1 (de) 2003-06-15

Family

ID=9480845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96924965T ATE240746T1 (de) 1995-07-10 1996-07-10 Immunovektoren zum transport in die zelle und den zellkern

Country Status (11)

Country Link
US (3) US6608034B1 (de)
EP (1) EP0837699B1 (de)
JP (3) JP2000506361A (de)
AT (1) ATE240746T1 (de)
CA (1) CA2224413C (de)
DE (1) DE69628298T2 (de)
DK (1) DK0837699T3 (de)
ES (1) ES2198495T3 (de)
FR (1) FR2736642B1 (de)
PT (1) PT837699E (de)
WO (1) WO1997002840A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
FR2766826B1 (fr) * 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
EP1006197A1 (de) * 1998-12-04 2000-06-07 Transgene S.A. Verwendung einer Immunkomplex zur Herstellung eines therapeutischen Mittels zur Verwendung für die Transfektion von einem Polynukleotid in Makropinozyte-Zellen
JP3513068B2 (ja) * 1999-05-12 2004-03-31 浜松ホトニクス株式会社 生細胞の細胞質内標的核酸を検出する方法
FR2805821B1 (fr) 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US20030032597A1 (en) * 2001-07-31 2003-02-13 Sebestyen Magdolna G. Targeting nucleic acids to a cellular nucleus
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
WO2003080115A1 (fr) * 2002-03-22 2003-10-02 Bipha Corporation Complexes peptide hydrophile - immunoglobuline
DE602004022056D1 (de) 2003-08-14 2009-08-27 Diatos Antibakterielle zusammensetzung, vor allem zur bekämpfung gramnegativer bakterien, umfassend ein peptid und ein vorteilhafterweise hydrophobes antibakterielles agens
EP1797901A1 (de) 2005-12-16 2007-06-20 Diatos Zelldurchlässige Peptidkonjugate zum Transfer von Nukleinsäuren in Zellen
EP1818395A1 (de) 2006-02-08 2007-08-15 Diatos Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen
ES2610779T3 (es) 2011-08-23 2017-05-03 President And Fellows Of Harvard College Nanopartículas de péptidos y usos de las mismas
MX382968B (es) 2012-11-16 2025-03-12 United Biomedical Inc Vacuna de emergencia basada en péptidos sintéticos contra la fiebre aftosa.
US20220227887A1 (en) * 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2334107A1 (fr) * 1975-12-05 1977-07-01 Pasteur Institut Procede de couplage de substances biologiques par des liaisons covalentes
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4599998A (en) * 1984-06-01 1986-07-15 Castillo James D Adjustable polycentric orthopedic appliance hinge
US4812397A (en) * 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
US4952499A (en) * 1988-02-11 1990-08-28 Dana-Farber Cancer Institute Genes and their encoded proteins which regulate gene expression of the interleukin-2 receptor and of human lymphotropic retroviruses
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
DE4104186A1 (de) * 1991-02-12 1992-08-13 Genentech Inc Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe
CA2108451A1 (en) * 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5922859A (en) 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
CA2140280A1 (en) * 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DE4318402A1 (de) * 1993-06-03 1994-12-08 Boehringer Mannheim Gmbh Verfahren zum Nachweis eines programmierten oder induzierten Zelltods eukaryontischer Zeller
US5681700A (en) * 1994-05-25 1997-10-28 Oklahoma Medical Research Foundation Assay for pathogenicity of anti-DNA antibodies
US5648219A (en) * 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
US5616819A (en) * 1995-08-28 1997-04-01 Laroche Industries Inc. Process for preparing fluorinated aliphatic compounds
JP2000507225A (ja) * 1996-03-08 2000-06-13 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ｍａｂ ３Ｅ１０ ならびにその突然変異体および／または機能性フラグメントを使用する送達システム
US5992859A (en) * 1998-04-27 1999-11-30 Chum Power Machinery Corp. Bit holding system for a power hand tool

Also Published As

Publication number Publication date
CA2224413C (fr) 2009-10-13
EP0837699A1 (de) 1998-04-29
ES2198495T3 (es) 2004-02-01
PT837699E (pt) 2003-09-30
FR2736642A1 (fr) 1997-01-17
JP2010115202A (ja) 2010-05-27
WO1997002840A1 (fr) 1997-01-30
EP0837699B1 (de) 2003-05-21
FR2736642B1 (fr) 1997-09-12
CA2224413A1 (fr) 1997-01-30
JP2008054684A (ja) 2008-03-13
US20110020928A1 (en) 2011-01-27
DE69628298T2 (de) 2004-03-25
US6608034B1 (en) 2003-08-19
US20040259822A1 (en) 2004-12-23
DK0837699T3 (da) 2003-09-22
JP2000506361A (ja) 2000-05-30
JP4680968B2 (ja) 2011-05-11
DE69628298D1 (de) 2003-06-26

Similar Documents

Publication Publication Date Title
ATE240746T1 (de) Immunovektoren zum transport in die zelle und den zellkern
ES530853A0 (es) Un metodo para separar una toxina bacteriana de una muestra biologica
DE69636621D1 (de) Verwendung von chimären proteinen im transport von ausgewählten substanten in die zelle
NZ334211A (en) Antibody fragment comprising a linear heavy chain associated with two light chain fragments
BR0008772B1 (pt) vetor de expressão, célula bacteriana ou fúngica cultivada, processos para expandir in vitro células hematopoiéticas e progenitores de células hematopoiéticas, e para detectar a presença de rna de ligando zalfa11 e de ligando zalfa 11 in vitro em uma amostra biológica.
DK609985A (da) Adhesin-antigener, antistoffer mod disse og dna-fragmenter, som indkoder antigenerne
BR9510408A (pt) Aperfeiçoamento na ou relativos á função endometrial
ATE58554T1 (de) Menschlicher hybridomfusionspartner zur herstellung menschlicher monoklonaler antikoerper.
MY106561A (en) Method of making factor-dependent human b cell lines
EP0174874A3 (de) Hybridzellinie die für Trichomonas vaginalis zytolytische, monoklonale Antikörper produziert
DK157888C (da) Fremgangsmaade til fremstilling af d-n-carbamoyl-alfa-aminosyrederivater og bakteriestammer til anvendelse i fremgangsmaaden
DE69821946D1 (de) Reduzierte fett-absorption durch anti-lipase antikörper
EP1176194A4 (de) Verfahren der zellkultivierung
PT83368A (en) Process for propagating microorganisms in vivo by using cell lines which lack human class ii histocompatibility antigens
EP0260599A3 (de) Verfahren und Mittel zum Nachweis von Antikörpern gegen menschliche und tierische Retroviren, insbesondere T-lymphotrope Viren
EP0855441A3 (de) Isolierung und Reinigung von Stammzellen mit magnetischen Kugeln, die wie Antikörper funktionieren, und Verfahren zur Preparation einer Stammzellinie
WO2002008416A1 (fr) Procede de preparation d'anticorps par immunisation genique
ATE36604T1 (de) Neues verfahren zum virus-nachweis in reinkulturen mikroskopischer kleinlebewesen sowie in lebensmitteln und in technologischen produkten.
DE59913949D1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
DE69923595D1 (de) Herstellung von proteinen
KR950031110A (ko) 인간 혈증 아포지단백질 비-100(b-100)에 대한 신규 단일클론 항체 및 이들의 생산을 위한 재조합 하이브리도마 세포주
UA31838A (uk) Спосіб діагностики симптоматичної епілепсії та епілептичних синдромів у дітей
NZ513502A (en) A method for introducing a nucleic acid into a mammalian neural stem cell or progenitor cell via the inherent transport mechanism of the cell
RU2001108231A (ru) Штамм гибридных клеток r1/s-5a6 животных mus musculus l., продуцирующих моноклональные антитела к риккетсиям провачека
MX9703956A (es) Genes purificados que codifican antigenos de superficie de celulas de mamiferos; proteinas y anticuerpos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0837699

Country of ref document: EP

REN Ceased due to non-payment of the annual fee